The Medicines and Healthcare Products Regulatory Agency, London,has announced that the migraine medication sumatriptan (Imigran) isto be reclassified from Prescription Only Medicine (POM) toPharmacy Medicine (P) status, making it available from pharmacieswithout the need for a prescription. With England setting aprecedent, will the United States be next?
The Medicines and Healthcare Products Regulatory Agency, London, has announced that the migraine medication sumatriptan (Imigran) is to be reclassified from Prescription Only Medicine (POM) to Pharmacy Medicine (P) status, making it available from pharmacies without the need for a prescription. With England setting a precedent, will the United States be next?
To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.
To go to the Drug Topics homepage, click here http://www.drugtopics.com.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.